|
Many of the most highly sought-after
proteins for therapeutics, characterization and diagnostics
prove some of the most difficult
to express. Problems
with structure, folding/re-folding, glycosylation,
immunogenicity, affinity, solubility, and activity continue to
plague researchers attempting to express these proteins. This
conference will present
strategies for improving the expression of these “finicky”
proteins, as well as providing researchers with opportunities to network
with groups which are successfully overcoming these
challenges.
Scientific Advisory Board
Kirill Alexandrov, Ph.D., The University of
Queensland
Deb Chatterjee, Ph.D., NCI
Lutz Jermutus, Ph.D., MedImmune
Ajith Kamath, Ph.D., Jubilant Biosys
Paul Ramage, Ph.D., Novartis Pharma AG
Karen
Sitney, Ph.D., Boehringer-Ingelheim
|
Keynote
Presentation
Biomanufacturing from Tobacco Biomass: Upstream
and Downstream Processing Challenges
Karen K. Oishi,
Ph.D., Associate Principal Scientist, Research and
Development, Philip Morris International (invited)
|
Protein
Engineering Approaches
Innovative Low Human Homology
Affinity Tags
Fons
Bosman, Ph.D., Formulation Expert, Biologicals,
Innogenetics NV
Fusion Proteins in Mammalian
Expression
Christopher Mehlin, Ph.D., Senior Scientist, Protein
Science, Amgen
Comparative Study on Autologous
Expression Improvement in Human Cells by Gene Optimization:
Results and Applications
Stephan Fath, Ph.D., Scientist Research & Development,
Geneart AG
Case
Studies
Secreted
Expression of Self-assembling Proteins in Pichia
Pastoris
Catarina Ferreira da Silva, M.Sc., Bioprocess
Engineering, Wageningen University and Research Centre
“Lost in Translation:” A Study
of Human Relaxin 2 and Frameshift Events Associated with the
lysyl-tRNA and the Rare Arginine Codon, AGA
John J. Kerrigan, Ph.D., Department of Biological Reagents
and Assay Development, GlaxoSmithKline
An Assessment of the Expression of
Two Human Therapeutic Proteins in Pfēnex Expression
Technology™
Christopher C. Frye, Ph.D., Senior Research Scientist,
Group Leader- Microbial Process Development, Eli Lilly and
Company
Expression and Characterization of
a Human BMP-7 Variant with Improved Biochemical Properties
Bethany Swencki-Underwood, Ph.D., Molecular Discovery
Technologies, Centocor Inc.
The
Feasibility of Expressing Membrane Proteins
Achieving Expression of Membrane
Proteins
James Bowie, Ph.D., Professor, Chemistry and Biochemistry,
University of California at Los Angeles
New
Expression Systems
A New Trichoplusia ni Cell
Line for Membrane Protein Expression using a Baculovirus
Expression Vector System
Suzanne M. Thiem, Ph.D., Department of Biochemistry and
Molecular Biology, Michigan State University
Controlling Transgene Expression
via Intragenic CpG Dinucleotides
Asli Bauer, Ph.D., Senior Scientist, Molecular Microbiology
and Gene Therapy, University of Regensburg
Expressing
Proteins for Structural Studies
Expression of Difficult, But
Medically Important, Proteins for Structural Studies
Opher Gileadi, Ph.D., University of Oxford
High Resolution Crystal Structure
of the Catalytic Domain of ADAMTS-5 (Aggrecanase-2); The
Refolding and Crystallization of a “Difficult
Protein”
Karl Mathis, BS,
Principal Scientist, Primary Pharmacology, Pfizer, Inc.
Blue Sky Biotech
Speaker and Title to be Announced
EMD Biosciences
Speaker and Title to be Announced
Preparation of Functional Human
Cannabinoid Receptor CB2 for Structural Studies
Alexei
Yeliseev, Ph.D., Staff Scientist, NIAAA, National Institutes
of Health For questions, please contact:
Elizabeth Lamb
Senior Conference Director
Cambridge Healthtech Institute
Fax: 207-493-7874
E-mail: elamb@healthtech.com
For sponsorship and
exhibit information, contact:
Carol Dinerstein
Cambridge Healthtech Institute
Phone: 781-972-5471
E-mail: dinerstein@healthtech.com
|
